Flexion Therapeutics Announces Clinical Hold Of FX006 Phase 2B Clinical Trial In Osteoarthritis Of The Knee
September 17, 2014 at 16:06 PM EDT
Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced that the United States Food and Drug Administration (FDA) informed the company ...